LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin Treatment
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Neoplasms
Interventions: DRUG: BIBW 2992|DRUG: trastuzumab|DRUG: vinorelbine|DRUG: vinorelbine
Sponsor: Boehringer Ingelheim